WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014190152) ANGIOTENSIN PEPTIDES IN TREATING MARFAN SYNDROME AND RELATED DISORDERS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2014/190152    International Application No.:    PCT/US2014/039141
Publication Date: 27.11.2014 International Filing Date: 22.05.2014
IPC:
A61K 38/12 (2006.01), A61K 38/55 (2006.01), A61K 38/00 (2006.01)
Applicants: TARIX PHARMACEUTICALS LTD. [US/US]; 12 Bow Street Cambridge, Massachusetts 02138 (US)
Inventors: FRANKLIN, Richard; (US)
Agent: REESE, Brian E.; Choate, Hall & Stewart LLP Two International Place Boston, Massachusetts 02110 (US)
Priority Data:
61/827,271 24.05.2013 US
Title (EN) ANGIOTENSIN PEPTIDES IN TREATING MARFAN SYNDROME AND RELATED DISORDERS
(FR) PEPTIDES ANGIOTENSINE DANS LE TRAITEMENT DU SYNDROME DE MARFAN ET DE TROUBLES ASSOCIÉS
Abstract: front page image
(EN)The present invention provides, among other things, methods of treating Marfan Syndrome and/or a Marfan-related disorder including administering to a subject suffering from or susceptible to Marfan Syndrome and/or a Marfan-related disorder an angiotensin (1-7) peptide. In some embodiments, the angiotensin (1-7) peptide is administered at an effective dose periodically at an administration interval such that at least one symptom or feature of Marfan Syndrome and/or a Marfan-related disorder is reduced in intensity, severity, duration, or frequency or has delayed in onset.
(FR)La présente invention concerne, entre autres, des méthodes de traitement du syndrome de Marfan et/ou d'un trouble associé à Marfan, comportant l'administration à un sujet souffrant ou susceptible de souffrir du syndrome de Marfan et/ou d'un trouble associé au syndrome de Marfan d'un peptide angiotensine (1-7). Dans certains modes de réalisation, le peptide angiotensine (1-7) est administré à une dose efficace périodiquement à un intervalle d'administration de telle sorte qu'au moins un symptôme ou une caractéristique du syndrome de Marfan et/ou du trouble associé à Marfan est réduite en intensité, en sévérité, en durée ou en fréquence ou son apparition est retardée.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)